IP Verse

Camulon competitive analysis

Explore patent oppositions filed by Camulon against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 10, 2026

Patent Number	Title	Applicant	Opposition Date
EP4403579	Formulation For Anti-Alpha4Beta7 Antibody	MILLENNIUM PHARMACEUTICALS	Sep 10, 2026
EP2396005	Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or Hyperglycemia	BOEHRINGER INGELHEIM	Aug 26, 2026
EP3694522	Bi-Layer Pharmaceutical Tablet Formulation	VIIV HEALTHCARE	Aug 26, 2026
EP4188389	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	ASTRAZENECA	Jun 17, 2026
EP4212152	Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure	NOVARTIS	Jan 27, 2026
EP4064849	Microorganism Oil Composition Enriched In Polyunsaturated Fatty Acids	POLARIS	Jan 16, 2026
EP4267105	Antibody Compositions And Methods Of Use Thereof	BRISTOL MYERS SQUIBB	Dec 19, 2025
EP3756650	Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione	AMGEN EUROPE	Oct 24, 2025
EP3539540	Pharmaceutical Composition, Methods For Treating And Uses Thereof	BOEHRINGER INGELHEIM	Sep 15, 2025
EP3411021	New Use Of A Combination Of Sacubitril And Valsartan	NOVARTIS	Sep 1, 2025

Discover the latest PTAB cases involving Camulon, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Camulon with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
CAMULON	21	-	-	-
APTALIS PHARMA	-	5	-	-
BOEHRINGER INGELHEIM	45	245	8	9
NOVARTIS	12	542	-	21